Back to Journals » OncoTargets and Therapy » Volume 6
Increased CD70 expression is associated with clinical resistance to cisplatin-based chemotherapy and poor survival in advanced ovarian carcinomas
Authors Liu N, Sheng X, Liu Y, Zhang X, Yu J
Received 24 February 2013
Accepted for publication 6 April 2013
Published 5 June 2013 Volume 2013:6 Pages 615—619
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Naifu Liu,1,* Xiugui Sheng,1,* Yi Liu,1 Xiaoling Zhang,1 Jinming Yu2
1Department of Gynecologic Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, People’s Republic of China; 2Shandong Cancer Hospital and Institute, Jinan, Shandong, People’s Republic of China
*These authors contributed equally to this work
Background: CD70 has been regarded as a novel potential therapeutic target for multiple cancers. In this study, we characterized the expression of the CD70 protein in ovarian carcinomas and assessed its clinical-pathological prognostic value.
Materials and methods: The expression of CD70 in advanced ovarian cancer specimens was assessed by immunohistochemistry. Our results indicated that 16 out of 92 (17.4%) advanced ovarian serous carcinoma tumors showed a high level of CD70 expression. Furthermore, CD70 overexpression was significantly associated with cisplatin-based chemotherapy responses. The high CD70 expression subgroup demonstrated a higher incidence of chemotherapy resistance than the low CD70 subgroup (68.8% versus 25.0%, P = 0.001). Furthermore, univariate analysis conducted on subsets of ovarian carcinoma indicated that high CD70 expression was also associated with decreased survival rates; retained significance was observed on multivariate analysis.
Conclusion: Given the elevated expression of CD70 and its relationship with drug resistance and poor prognosis, our findings suggest that a minor proportion of ovarian carcinomas with CD70 overexpression might be a candidate for the emerging anti-CD70 antibody drug conjugates or therapeutic anti-CD70 antibodies.
Keywords: ovarian carcinoma, CD70, immunohistochemistry, survival, chemotherapy resistance
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.